Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.

Seoyoung LeeHyo Sup ShimBeung-Chul AhnSun Min LimHye Ryun KimByoung Chul ChoMin Hee Hong

Published in: Cancer immunology, immunotherapy : CII (2021)

Atezolizumab, combined with etoposide and carboplatin, showed efficacy and safety in our real-world data. Further studies are needed to predict the response to immunotherapy in SCLC.

Keyphrases

small cell lung cancer
phase ii study
phase iii
electronic health record
big data
brain metastases
open label
case control
locally advanced
clinical trial
squamous cell carcinoma
machine learning
double blind